IE20001017A1 - Matrix tablet enabling the prolonged release of trimetazidine after administration by the oral route - Google Patents
Matrix tablet enabling the prolonged release of trimetazidine after administration by the oral routeInfo
- Publication number
- IE20001017A1 IE20001017A1 IE20001017A IE20001017A IE20001017A1 IE 20001017 A1 IE20001017 A1 IE 20001017A1 IE 20001017 A IE20001017 A IE 20001017A IE 20001017 A IE20001017 A IE 20001017A IE 20001017 A1 IE20001017 A1 IE 20001017A1
- Authority
- IE
- Ireland
- Prior art keywords
- matrix tablet
- tablet according
- trimetazidine
- matrix
- percentage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a matrix tablet enabling the prolonged release of trimetazidine, or an addition salt thereof with a pharmaceutically acceptable acid, after administration by the oral route, characterised in that the prolonged release is controlled by the use of a cellulose derivative polymer.
Description
The present invention relates to a matrix tablet enabling the prolonged release of trimetazidine, or an addition salt thereof with a pharmaceutically acceptable acid, after administration by the oral route.
Trimetazidine, or l-(2,3,4-trimethoxybenzyl)piperazine, is a compound which, by maintaining the energy metabolism of a cell exposed to hypoxia or ischaemia, avoids the collapse of the intracellular level of adenosine triphosphate (ATP). It thus ensures functioning of the ion pumps and sodium-potassium transmembrane flows and maintains cellular homeostasis.
Trimetazidine dihydrochloride is currently used therapeutically for the prophylactic treatment of angina pectoris crisis, in chorioretinal attacks and for the treatment of vertigo of vascular origin (Meniere's vertigo, tinnitus).
Trimetazidine dihydrochloride has, until now, been administered by the oral route at doses of from 40 to 60 mg/day, in the form of tablets containing 20 mg of active ingredient or a drinkable solution containing 20 mg of active ingredient per ml. Those two forms are immediate-release forms. Patent FR 2 490 963 describes the immediate-release tablet form. Trimetazidine dihydrochloride is rapidly absorbed and eliminated by the body, its plasma half-life being less than 6 hours, which means that administration of the active ingredient has to be split into 2 or 3 administrations per day in order to ensure sufficient plasma levels. The dosage regimen most frequently required during treatments is three tablets per day. Multiple daily administrations bear the risk of being forgotten both by patients leading an active life and by elderly patients already taking a number of medications.
Because of the rapid absorption and the 6-hour half-life, such immediate-release forms result in low levels in the blood by the time of the next administration. It is known to be important to maintain effective myocardial protection throughout the 24-hour period and especially in the early morning when the consequences of ischaemia are most serious. Because complete coverage of the day is not achieved with the immediate-release form, the Applicant has developed a prolonged-release form enabling perfect 24-hour coverage, ensuring a sufficient level in the blood between two administrations whilst retaining a large -2plasma peak after each administration so as to maintain the efficacy of the trimetazidine, maintaining the energy metabolism of a cell exposed to hypoxia or ischaemia and avoiding the lowering of the intracellular level of ATP.
It also allows peripheral vasodilator effects to be avoided, while stabilising blood flow rates and tensional effects.
IE 0 ο 1 0 1 The new formulation according to the invention accordingly allows the positive characteristics of the formulation described in patent PR 2 490 963 to be retained while enabling better coverage of the day, which leads to better compliance and permanent protection.
The present invention relates more especially to a matrix tablet which enables the prolonged release of trimetazidine, or a pharmaceutically acceptable salt thereof) after administration by the oral route and which is composed of a hydrophilic matrix characterised in that the prolonged release is controlled by the use of a cellulose derivative polymer.
This matrix tablet, administrable preferably twice a day, enables prolonged active ingredient release to be obtained whilst retaining a large plasma peak on each administration. It allows plasma levels greater than 70 pg/l to be obtained in humans after each administration and a plasma level greater than or equal to 40 pg/l to be maintained until the next administration, which was not the case with the tablet described in patent FR 2 490 963 when administered 3 times per day.
Among the cellulose derivatives used in the matrix according to the invention, there may be mentioned, more especially, cellulose ethers such as hydroxypropylcellulose, hydroxyethylcellulose, hydroxymethylcellulose, methylcellulose and hydroxypropyl methylcellulose.
The cellulose derivative is preferably hydroxypropyl methylcellulose. The percentage of cellulose derivative polymer is from 25 to 50 % of the total mass of the tablet. -3Hydroxypropyl methylcelluloses that have a viscosity of from 100 cP to 100 000 cP may be used. The preferred viscosity is 4 000 cP.
Various excipients are added to the hydrophilic matrix, for example binders, diluents, lubricants and flow agents. Among the binders, polyvidone is preferably used. The percentage of polyvidone is from 3 to 12 % of the total mass of the tablet. Among the diluents, calcium hydrogen phosphate dihydrate is preferably used, which provides better fluidity and better compressibility than other diluents such as lactose monohydrate. The percentage of calcium hydrogen phosphate is from 25 to 75 % of the total mass of the tablet.
Among the lubricants, there may be mentioned, without implying any limitation, magnesium stearate, stearic acid, glycerol behenate and sodium benzoate. The preferred lubricant is magnesium stearate. Finally, colloidal silica is preferably used as flow agent.
The trimetazidine used in the matrix tablets according to the invention is preferably in the dihydrochloride form.
The percentage of trimetazidine dihydrochloride is from 15 to 30 % of the total mass of the tablet, preferably from 15 to 18 %.
The person skilled in the art will generally consider the release kinetics of matrix tablets to be dependent on the nature and amount of the basic component of the matrix - in this case, namely, the cellulose derivative.
It now appears, surprisingly, that the release kinetics of the matrix tablet according to the invention are influenced neither by the amount nor by the grade of the cellulose derivative used.
Various formulations produced using, on the one hand, hydroxypropyl methylcelluloses of different viscosities and, on the other hand, variable amounts of the same grade of IE Ο 0 1 ο 1 7 -4hydroxypropyl methylcellulose have exhibited equivalent release kinetics, which implies that there exists a specific synergy between the cellulose derivative and the trimetazidine.
The present invention relates also to a process for the preparation of the matrix tablet. The matrix tablet may be prepared by wet granulation followed by compression, by dry granulation followed by compression, or by direct compression. The preparation process is preferably wet granulation followed by compression.
The wet granulation is performed by mixing the trimetazidine, the polyvidone and the diluent, and then wetting that mixture. That first step enables a hydrophilic environment to be created around the active ingredient, which is beneficial for its dissolution, and also enables a unit dose that is as uniform as possible to be obtained.
In a second step, the previously obtained granulate is mixed with the cellulose derivative.
The lubricant and the flow agent are then added to the mixture. The third step is compression of the lubricated mixture previously obtained.
The tablets thus formed are then, if desired, coated according to a conventional coating 15 technique.
The following Examples illustrate the invention but do not limit it in any way. The matrix tablets described in the Examples were prepared in the following manner: - Step A : Mixture of trimetazidine, polyvidone and calcium hydrogen phosphate dihydrate, then wetting of the mixture using a sufficient amount of purified water, granulation and then drying of the granulate.
- StevB: Mixture of the granulate obtained in Step A with hydroxypropyl methylcellulose.
• ‘Steg C : Lubrication of the mixture obtained in Step B with magnesium stearate and colloidal silica. -5-Step D : Compression of the lubricated mixture obtained in Step C on a rotary tablet machine so as to obtain tablets having a hardness of about from 40 to 160 N, measured by breaking across a diameter.
EXAMPLE 1: Formulations of different matrix tablets containing various amounts 5 of trimetazidine Table 1: Unitary formulae for 3 types of tablet Compound Amount (mg) Fj i i F* f3 Trimetazidine dihydrochloride 60 1 30 35 Hydroxypropyl methylcellulose 112 ! 74 ί 74 Polyvidone 13.3 Ϊ 8.7 8.7 Calcium hydrogen phosphate dihydrate 92 ! 85.9 ! 80.9 Magnesium stearate 2.2 ΐ 1 1 Anhydrous colloidal silica 0.5 j 0.4 0.4 Γοία/ mass of ihe tablet 280 1 200 J 200 _ EXAMPLE!: Example 2 shows that different amounts of hydroxypropyl methylcellulose do not have an io influence on the dissolution kinetics of the tablet.
Table 2: Unitary formulae / variable amounts of HPMC Compound Amount (mg) f4 f5 Trimetazidine dihydrochloride 35 35 Hydroxypropyl methylcellulose 54 94 Polyvidone 10.1 7.3 Calcium hydrogen phosphate dihydrate 99.5 62.3 Magnesium stearate 1 1 Anhydrous colloidal silica 0.4 0.4 Total mass of ihe tablet 200 200 Table 3 shows the percentages of compound released as a function of time for the formulations F4 and F5.
IE Ο Ο 1 011 -6Table 3 : Release kinetics Time(h) Percentage of compound released (%) .....*4 Fs 1 41 38 2 59 59 3 80 77 4 97 96 EXAMPLES: Example 3 shows that different grades of hydroxypropyl methylcellulose do not have an influence on the dissolution kinetics ofthe tablet.
Table 4: Formulations / variable grades of HPMC Compound Amount (mg) F3 Fe f7 Trimetazidine dihydrochloride 35 35 35 Hydroxypropyl methylcellulose 4000 cP 74 - - Hydroxypropyl methylcellulose 100 cP - - 74 Hydroxypropyl methylcellulose 100 000 cP - 74 - Polyvidone 8.7 8.7 8.7 Calcium hydrogen phosphate dihydrate 80.9 80.9 80.9 Magnesium stearate 1 1 1 Anhydrous colloidal silica 0.4 0.4 0.4 Table 5 shows the percentages of compound released as a function of time for the formulations F3, Fe and F7.
Table 5: Release kinetics Time (h) Percentage of compound released (%) f3 F6 f7 1 43 41 40 2 62 59 60 3 86 83 83 4 105 102 100 \E0 0 1 0 1 7 -7EXAMPLE 4 : Plasma kinetics study The plasma kinetics were studied after administration of the matrix tablet of formulation F3 described in Example 1 to 12 healthy volunteers.
Administration was carried out for 4 days at the rate of two tablets per day.
The plasma kinetics of the tablet of formula F3 were compared to those of an immediaterelease (IR) tablet administered for 4 days at the rate of three tablets per day.
The unitary formulation of the immediate-release (IR) tablet is as follows: Trimetazidine dihydrochloride............................................................................20 mg Maize starch........................................................................................................26 mg Mannitol.............................................................................................................34 mg Polyvidone............................................................................................................4 mg Magnesium stearate..............................................................................................1 mg Talc.......................................................................................................................5 mg The average plasma concentration is given in Figure 1, which shows the plasma kinetics of trimetazidine, showing average plasma concentrations of trimetazidine (in pg/l) after oral administration of the F3 form and an IR form to 12 healthy volunteers. The curve clearly shows that the F3 form enables prolonged release of trimetazidine to be obtained while retaining a large plasma peak on each administration.
The plasma level observed after each administration is close to 90 pg/l and hardly different from that obtained with the IR form. At the end of 24 hours the plasma level is greater than 40 pg/l whereas, with the immediate-release formulation, it is only about 25 gg/l.
The invention is not limited to the embodiments hereinbefore described which may be varied within the scope of the appended claims.
Claims (17)
1.I- Matrix tablet for the prolonged release of trimetazidine or a pharmaceutically acceptable salt thereof, characterised in that the prolonged release is controlled by the use of a cellulose derivative polymer. 5
2. - Matrix tablet according to claim 1, characterised in that the cellulose derivative polymer is a hydroxypropyl methylcellulose.
3. - Matrix tablet according to either claim 1 or claim 2, characterised in that the percentage of cellulose derivative is from 25 to 50 % of the total mass of the tablet.
4. - Matrix tablet according to any preceding claim, characterised in that it also comprises a 10 binder, a diluent, a lubricant and a flow agent.
5. - Matrix tablet according to claim 4, characterised in that the binder is polyvidone.
6. - Matrix tablet according to claim 5, characterised in that the percentage of polyvidone is from 3 to 12 % of the total mass of the tablet.
7. - Matrix tablet according to any one of claims 4, 5 or 6, characterised in that the diluent is 15 calcium hydrogen phosphate dihydrate.
8. - Matrix tablet according to claim 7, characterised in that the percentage of calcium hydrogen phosphate dihydrate is from 25 to 75 % of the total mass of the tablet.
9. - Matrix tablet according to any one of claims 4, 5, 6, 7 or 8, characterised in that the lubricant is magnesium stearate and the flow agent is anhydrous colloidal silica. -910- Matrix tablet according to any preceding claim, characterised in that the trimetazidine is in the dihydrochloride form.
10. 11- Matrix tablet according to claim 10, characterised in that the percentage of trimetazidine dihydrochloride is from 15 to 30 % of the total mass of the tablet.
11. 12- Matrix tablet according to claim 10 or 11 characterised in that the percentage of trimetazidine dehydrochloride is from 15 to 18% of the total mass of the tablet.
12. 13- Matrix tablet according to any of claims 10 to 12, characterised in that the percentage of trimetazidine dihydrochloride is 17.5 % of the total mass of the tablet.
13. 14- Matrix tablet according to any preceding claim, characterised in that it contains 35 mg of trimetazidine dihydrochloride, 74 mg of hydroxypropyl methylcellulose, 8.7 mg of polyvidone, 80.9 mg of calcium hydrogen phosphate dihydrate, 1 mg of magnesium stearate and 0.4 mg of anhydrous colloidal silica.
14. 15- Matrix tablet according to claim 14, characterised in that it is administered twice per day.
15. 16- Matrix tablet according to any preceding claim, characterised in that it enables plasma levels greater than 70 μg/1 to be obtained in humans after each administration and a plasma level greater than or equal to 40 pg/l to be maintained until the next administration.
16. 17- Process for the preparation of a matrix tablet according to any one of claims 1 to 14, characterised in that: - wet granulation is carried out by mixing trimetazidine, polyvidone and the diluent and then wetting that mixture, - the granulate thus obtained is mixed with the cellulose derivative, - the lubricant and the flow agent are then added, - the previous mixture is then compressed. -1018-Matrix tablet according to any one of claims 1 to 16 for use in the prophylactic treatment of angina pectoris, in chorioretinal attacks and in the treatment of vertigo of vascular origin. 5 19- A matrix tablet substantially as hereinbefore described with reference to the examples and drawings.
17. 20- A process for the manufacture of a matrix tablet substantially as hereinbefore described with reference to the examples and drawings. CRUICKSHANK & CO.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9915960A FR2802424B1 (en) | 1999-12-17 | 1999-12-17 | MATRIX TABLET FOR THE EXTENDED RELEASE OF TRIMETAZIDINE AFTER ORAL ADMINISTRATION |
Publications (1)
Publication Number | Publication Date |
---|---|
IE20001017A1 true IE20001017A1 (en) | 2002-04-03 |
Family
ID=9553398
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IE20001017A IE20001017A1 (en) | 1999-12-17 | 2000-12-15 | Matrix tablet enabling the prolonged release of trimetazidine after administration by the oral route |
Country Status (33)
Country | Link |
---|---|
EP (1) | EP1108424B2 (en) |
JP (2) | JP2001172181A (en) |
KR (1) | KR100456933B1 (en) |
CN (1) | CN1166408C (en) |
AR (1) | AR026968A1 (en) |
AT (1) | ATE296622T1 (en) |
AU (1) | AU780011B2 (en) |
BG (1) | BG65773B1 (en) |
BR (1) | BR0005915A (en) |
CY (1) | CY2347B1 (en) |
CZ (1) | CZ299461B6 (en) |
DE (1) | DE60020501T3 (en) |
DK (1) | DK1108424T4 (en) |
EA (2) | EA008223B1 (en) |
ES (2) | ES2240033T5 (en) |
FR (1) | FR2802424B1 (en) |
GE (1) | GEP20053540B (en) |
GR (1) | GR1003658B (en) |
HK (1) | HK1036937A1 (en) |
HU (1) | HU226956B1 (en) |
IE (1) | IE20001017A1 (en) |
IT (1) | IT1317075B1 (en) |
LU (1) | LU90700B1 (en) |
MX (1) | MXPA00012462A (en) |
NZ (1) | NZ508912A (en) |
OA (1) | OA12121A (en) |
PL (1) | PL206994B1 (en) |
PT (2) | PT1108424E (en) |
SI (1) | SI1108424T2 (en) |
SK (1) | SK286752B6 (en) |
UA (1) | UA80087C2 (en) |
WO (1) | WO2001043747A1 (en) |
ZA (1) | ZA200007548B (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE442852T1 (en) * | 2000-10-05 | 2009-10-15 | Usv Ltd | DELAYED-RELEASE MEDICINAL COMPRISING TRIMETAZIDINE AND METHOD FOR THE PRODUCTION |
KR101175816B1 (en) * | 2003-08-04 | 2012-08-24 | 교린 세이야꾸 가부시키 가이샤 | Sustained release tablet for oral use |
SG126792A1 (en) * | 2005-04-27 | 2006-11-29 | Servier Lab | Matrix tablet enabling the prolonged release of trimetazidine after administration by the oral route |
FR2885807B1 (en) * | 2005-05-18 | 2008-05-16 | Mg Pharma | SOLID PHARMACEUTICAL COMPOSITION WITH PROLONGED RELEASE OF 1- (2,3,4-TRIMETHOXYBENZYL) PIPERAZINE, AND PREPARATION METHOD |
CZ300307B6 (en) * | 2006-01-04 | 2009-04-15 | Zentiva, A. S. | Modified release tablet containing trimetazidine or pharmacologically acceptable salts thereof |
EA009776B1 (en) * | 2006-07-18 | 2008-04-28 | Мераб Ревазович Кокеладзе | Method for preparing tablets of dihydrochloride trimethazine and composition thereof |
EA009810B1 (en) * | 2006-12-26 | 2008-04-28 | Закрытое Акционерное Общество "Канонфарма Продакшн" | Matrix for manufacturing tableted dosage form and method of treatment |
EP2200591A2 (en) * | 2007-09-11 | 2010-06-30 | Ranbaxy Laboratories Limited | Controlled release pharmaceutical dosage forms of trimetazidine |
JP2012515757A (en) | 2009-01-20 | 2012-07-12 | マイクロ ラブス リミテッド | Trimetazidine controlled release solid pharmaceutical composition and method for producing the same |
HUE027498T2 (en) * | 2009-01-30 | 2016-10-28 | Lupin Ltd | Pharmaceutical compositions of trimetazidine |
TR201001902A2 (en) | 2010-03-12 | 2011-04-21 | Ali̇ Rai̇f İlaç Sanayi̇ Ve Ti̇caret A.Ş. | Trimetazidine tablets with extended release |
RU2445958C2 (en) * | 2010-04-20 | 2012-03-27 | Общество с ограниченной ответственностью "Озон" (ООО "Озон") | Matrix tablet with trimetazidine prolonged-release base and method for preparing it |
ES2508490T3 (en) | 2010-05-04 | 2014-10-16 | Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi | Formulation of trimetazidine with different release profiles |
EP2386302A1 (en) | 2010-05-11 | 2011-11-16 | Ranbaxy Laboratories Limited | A controlled release pharmaceutical dosage form of trimetazidine and processes for the preparation thereof |
EP2491930A1 (en) | 2011-02-25 | 2012-08-29 | Deva Holding Anonim Sirketi | Pharmaceutical combination of betahistine and trimetazidine |
FR2978916B1 (en) * | 2011-08-10 | 2013-07-26 | Servier Lab | SOLID PHARMACEUTICAL COMPOSITION FOR BUCCAL ADMINISTRATION OF AGOMELATIN |
FR2986431B1 (en) * | 2012-02-03 | 2017-03-17 | Servier Lab | PROLONGED RELEASE OF TRIMETAZIDINE PHARMACEUTICAL COMPOSITION, PROCESS FOR THE PRODUCTION THEREOF AND USE IN THERAPEUTIC TREATMENTS |
CN102824644B (en) * | 2012-09-13 | 2013-12-25 | 浙江诚意药业有限公司 | High-stability sustained-release tablet prepared by using hydroxy propyl cellulose |
KR20160118733A (en) | 2015-04-03 | 2016-10-12 | 이인현 | Hose guide apparatus for hose winder and hose winder |
CN109316455B (en) * | 2017-07-31 | 2021-05-25 | 北京福元医药股份有限公司 | Trimetazidine hydrochloride sustained release tablet |
CN109908096A (en) * | 2017-12-12 | 2019-06-21 | 武汉武药科技有限公司 | A kind of trimetazidine hydrochloride sustained-release tablets and preparation method thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4226849A (en) * | 1979-06-14 | 1980-10-07 | Forest Laboratories Inc. | Sustained release therapeutic compositions |
FR2490963B1 (en) * | 1980-09-30 | 1986-04-18 | Science Union & Cie | NOVEL THERAPEUTIC COMPOSITION WITH ANTI-ISCHEMIC ACTION CONTAINING TRIMETHOXY 2, 3, 4-BENZYL 1-PIPERAZINE |
KR850006132A (en) * | 1984-02-29 | 1985-10-02 | 진 크라메르, 한스 루돌프 하우스 | Bromocriptine Composition |
JPS61293931A (en) * | 1985-06-24 | 1986-12-24 | Teijin Ltd | Slow-releasing pharmaceutical composition |
JPH0625055B2 (en) * | 1985-03-18 | 1994-04-06 | 日本ケミフア株式会社 | Persistent tablets |
EP0207638B1 (en) † | 1985-06-04 | 1990-12-19 | Teijin Limited | Sustained-release pharmaceutical preparation |
SE455836B (en) * | 1985-10-11 | 1988-08-15 | Haessle Ab | PREPARATION WITH CONTROLLED RELEASE CONTAINING A SALT OF METOPROLOL AND METHOD FOR PREPARING THIS PREPARATION |
SE8601624D0 (en) * | 1986-04-11 | 1986-04-11 | Haessle Ab | NEW PHARMACEUTICAL PREPARATIONS |
FR2677886B1 (en) * | 1991-06-18 | 1995-03-31 | Adir | MATRIX TABLET FOR THE EXTENDED RELEASE OF INDAPAMIDE AFTER ORAL ADMINISTRATION. |
FR2681324B1 (en) * | 1991-09-18 | 1993-10-29 | Adir Cie | NOVEL TRIMETAZIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
KR940021051A (en) * | 1993-03-03 | 1994-10-17 | 손정삼 | 3-step drug release sustained tablet |
RU2082400C1 (en) * | 1993-12-16 | 1997-06-27 | Акционерное общество - Фармацевтическая фирма "Ник-Фарм" | Method of nitroglycerol prolonged action preparing |
FR2717687B1 (en) * | 1994-03-24 | 1996-06-14 | Adir | Pharmaceutical compositions for the sustained release of trimetazidine after oral administration. |
-
1999
- 1999-12-17 FR FR9915960A patent/FR2802424B1/en not_active Expired - Fee Related
-
2000
- 2000-12-11 JP JP2000375812A patent/JP2001172181A/en active Pending
- 2000-12-14 AU AU72285/00A patent/AU780011B2/en not_active Expired
- 2000-12-14 MX MXPA00012462A patent/MXPA00012462A/en active IP Right Grant
- 2000-12-14 IT IT2000RM000667A patent/IT1317075B1/en active
- 2000-12-14 CY CY0000059A patent/CY2347B1/en unknown
- 2000-12-15 LU LU90700A patent/LU90700B1/en active
- 2000-12-15 OA OA1200200181A patent/OA12121A/en unknown
- 2000-12-15 DE DE60020501.0T patent/DE60020501T3/en not_active Expired - Lifetime
- 2000-12-15 CZ CZ20022082A patent/CZ299461B6/en not_active IP Right Cessation
- 2000-12-15 NZ NZ508912A patent/NZ508912A/en not_active IP Right Cessation
- 2000-12-15 KR KR10-2000-0076962A patent/KR100456933B1/en active IP Right Review Request
- 2000-12-15 ZA ZA200007548A patent/ZA200007548B/en unknown
- 2000-12-15 GE GE4838A patent/GEP20053540B/en unknown
- 2000-12-15 AT AT00403533T patent/ATE296622T1/en active
- 2000-12-15 PT PT00403533T patent/PT1108424E/en unknown
- 2000-12-15 DK DK00403533.3T patent/DK1108424T4/en active
- 2000-12-15 UA UA2002075914A patent/UA80087C2/en unknown
- 2000-12-15 GR GR20000100433A patent/GR1003658B/en unknown
- 2000-12-15 PL PL344564A patent/PL206994B1/en not_active IP Right Cessation
- 2000-12-15 WO PCT/FR2000/003546 patent/WO2001043747A1/en active IP Right Grant
- 2000-12-15 HU HU0004966A patent/HU226956B1/en active IP Right Maintenance
- 2000-12-15 ES ES00403533.3T patent/ES2240033T5/en not_active Expired - Lifetime
- 2000-12-15 PT PT102542A patent/PT102542A/en not_active IP Right Cessation
- 2000-12-15 SI SI200030704T patent/SI1108424T2/en unknown
- 2000-12-15 CN CNB001380605A patent/CN1166408C/en not_active Expired - Lifetime
- 2000-12-15 IE IE20001017A patent/IE20001017A1/en not_active Application Discontinuation
- 2000-12-15 SK SK863-2002A patent/SK286752B6/en not_active IP Right Cessation
- 2000-12-15 AR ARP000106662A patent/AR026968A1/en not_active Application Discontinuation
- 2000-12-15 ES ES200003018A patent/ES2176106B1/en not_active Expired - Fee Related
- 2000-12-15 EP EP00403533.3A patent/EP1108424B2/en not_active Expired - Lifetime
- 2000-12-18 EA EA200001201A patent/EA008223B1/en not_active IP Right Cessation
- 2000-12-18 EA EA200501901A patent/EA200501901A1/en unknown
- 2000-12-18 BR BR0005915-3A patent/BR0005915A/en not_active Application Discontinuation
-
2001
- 2001-11-12 HK HK01107928A patent/HK1036937A1/en not_active IP Right Cessation
-
2002
- 2002-07-16 BG BG106927A patent/BG65773B1/en unknown
-
2007
- 2007-08-31 JP JP2007224959A patent/JP2007314578A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU780011B2 (en) | Matrix tablet enabling the prolonged release of trimetazidine after administration by the oral route | |
EP1274402B1 (en) | Pharmaceutical composition for the controlled release of paracetamol | |
GB2209940A (en) | Sustained release etodolac | |
CZ403498A3 (en) | Quick soluble tablet containing galanthamine hydrobromide | |
AU2001260212A1 (en) | Composition | |
CA2182004C (en) | Film coated tablet of paracetamol and domperidone | |
HUT72635A (en) | Compositions containing alfuzonin-hydrochloride of sustained release | |
CA1272957A (en) | Controlled-release dosage form comprising acetaminophen, pseudoephedrine and dexbrompheniramine | |
JPH0757726B2 (en) | Sustained release tablets based on high molecular weight hydroxypropyl methylcellulose | |
KR20050035250A (en) | Bicifadine formulation | |
WO2005011666A1 (en) | Stable sustained release oral dosage form of gabapentin | |
WO2020148217A1 (en) | A method of manufacturing a pharmaceutical composition comprising nefopam and acetaminophen, and the pharmaceutical composition obtained thereby | |
WO2000013675A1 (en) | Methazolamide compositions and method of use | |
EP1406635A2 (en) | A controlled release anti-inflammatory formulation and a process for the preparation thereof | |
KR20050085386A (en) | Method and compositions for treating anxiety |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC9A | Application refused sect. 31(1) |